Zentalis Pharmaceuticals (ZNTL) to Release Earnings on Wednesday

Zentalis Pharmaceuticals (NASDAQ:ZNTL) is anticipated to post its Q1 2026 results before the market opens on Wednesday, May 13th. Analysts expect the company to announce earnings of ($0.49) per share for the quarter. Interested persons may visit the the company’s upcoming Q1 2026 earning results page for the latest details on the call scheduled for Thursday, May 14, 2026 at 4:00 PM ET.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last posted its earnings results on Thursday, March 26th. The company reported ($0.49) earnings per share for the quarter, missing the consensus estimate of ($0.41) by ($0.08). On average, analysts expect Zentalis Pharmaceuticals to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Zentalis Pharmaceuticals Price Performance

Shares of Zentalis Pharmaceuticals stock opened at $4.09 on Wednesday. The company has a market capitalization of $291.17 million, a P/E ratio of -2.15 and a beta of 1.99. Zentalis Pharmaceuticals has a 1 year low of $1.13 and a 1 year high of $6.95. The business has a 50-day moving average of $3.22 and a two-hundred day moving average of $2.36.

Insider Transactions at Zentalis Pharmaceuticals

In related news, insider Vincent Vultaggio sold 29,951 shares of the stock in a transaction that occurred on Friday, February 6th. The stock was sold at an average price of $2.43, for a total transaction of $72,780.93. Following the completion of the transaction, the insider directly owned 156,779 shares of the company’s stock, valued at approximately $380,972.97. This represents a 16.04% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders sold a total of 43,521 shares of company stock worth $105,539 in the last 90 days. Corporate insiders own 1.90% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the company. Voleon Capital Management LP acquired a new position in shares of Zentalis Pharmaceuticals during the 3rd quarter worth about $41,000. Qube Research & Technologies Ltd bought a new position in shares of Zentalis Pharmaceuticals during the 2nd quarter worth approximately $37,000. Algert Global LLC acquired a new position in shares of Zentalis Pharmaceuticals during the 3rd quarter worth approximately $73,000. Corient Private Wealth LLC acquired a new position in shares of Zentalis Pharmaceuticals during the 2nd quarter worth approximately $83,000. Finally, Opal Capital LLC bought a new stake in Zentalis Pharmaceuticals in the 4th quarter valued at $98,000.

Wall Street Analyst Weigh In

A number of equities research analysts recently issued reports on the company. Wall Street Zen lowered Zentalis Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Saturday, March 28th. Wells Fargo & Company initiated coverage on shares of Zentalis Pharmaceuticals in a research note on Tuesday, March 17th. They set an “equal weight” rating and a $5.00 price target for the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Zentalis Pharmaceuticals in a report on Tuesday, April 7th. Finally, Guggenheim increased their target price on shares of Zentalis Pharmaceuticals from $6.00 to $10.00 and gave the stock a “buy” rating in a report on Friday, April 10th. One equities research analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company has an average rating of “Hold” and a consensus target price of $5.83.

Zentalis Pharmaceuticals Company Profile

Zentalis Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics for oncology. Leveraging a proprietary structure-based drug discovery platform, the company designs selective inhibitors aimed at critical cancer targets. Zentalis’ research and development efforts center on delivering differentiated therapies that address unmet medical needs in solid tumors and hematologic malignancies.

The company’s lead product candidate, ZN-c3, is an orally administered inhibitor of the p53-MDM2 interaction, currently being evaluated in Phase I clinical trials for advanced solid tumors and hematologic cancers.